Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | BRD4 | O60885 | 5/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.50 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.49 |
| ▸ | TAF1 | P21675 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TTK | P33981 | 1/20 | 0.48 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.48 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.48 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13880647 | 0.96 | AURKA (0.52) | HTR4AURKAAURKBLRRK2ROCK2 | |
| SCHEMBL13461288 | 0.93 | SLC6A5 (0.51) | HTR4AURKAAURKBLRRK2ROCK2 | |
| SCHEMBL13846090 | 0.93 | HTR4 (0.54) | HTR4AURKAAURKBLRRK2MCHR1 | |
| SCHEMBL13175736 | 0.93 | HTR4 (0.54) | HTR4AURKAAURKBLRRK2MCHR1 | |
| SCHEMBL3544670 | 0.93 | HTR4 (0.54) | HTR4AURKAAURKBLRRK2MCHR1 | |
| SCHEMBL2546256 | 0.90 | MAPK14 (0.52) | HTR4LRRK2KMT2A | |
| SCHEMBL12893788 | 0.89 | HTR4 (0.48) | HTR4AURKAAURKBLRRK2MCHR1 | |
| SCHEMBL12894062 | 0.89 | HTR4 (0.48) | HTR4AURKAAURKBLRRK2MCHR1 | |
| SCHEMBL12825174 | 0.88 | KMT2A (0.57) | KMT2A | |
| SCHEMBL1927002 | 0.88 | KMT2A (0.54) | HTR4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145625-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-05-08 | — | — | US | disclosed |
| EP-4458827-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2024-11-06 | — | — | EP | disclosed |
| US-RE50082-E1 | (5,6-dihydro)pyrimido[4,5-e]indolizines | NETHERLANDS TRANSLATIONAL RESEARCH CENTER B.V. (NL) | 2024-08-20 | — | — | US | disclosed |
| CN-118414337-A | Pyrazolopyrimidine derivative and anticancer pharmaceutical composition containing same as active ingredient | 韩国化学研究院 | 2024-07-30 | — | — | CN | disclosed |
| CN-117043163-A | Pyrrolopyrimidine or pyrrolopyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023128708-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | 한국화학연구원 | 2023-07-06 | — | — | WO | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| WO-2023036252-A1 | PYRROLOPYRIMIDINE OR PYRROLOPYRIDINE DERIVATIVE AND MEDICAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-03-16 | — | — | WO | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| WO-2008113711-A1 | SUBSTITUTED PYRIMIDODIAZEPINES USEFUL AS PLK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-09-25 | — | — | WO | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008009909-A1 | PTERIDIMONES AS MODULATORS OF POLO-LIKE KINASE | ASTRAZENECA AB (SE) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
| WO-2007120752-A2 | 4, 5-DIHYDRO- [1, 2, 4] TRIAZOLO [4, 3-F] PTERIDINES AS PROTEIN KINASE PLK1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007095188-A2 | DIHYDRODIAZEPINES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145625-A1 | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DPYD, TP53, WASHC5 | HTR4 4098/4885AURKA 794/4885AURKB 1680/4885 |
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | HTR4 3043/4885AURKA 2926/4885AURKB 1213/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | HTR4 707/4885AURKA 107/4885AURKB 27/4885 |
| US-20080177066-A1 | Process for the manufacture of dihydropteridinones | QDPR, DHPS, DHODH | HTR4 2316/4885AURKA 4467/4885AURKB 4310/4885 |
| US-20060047118-A1 | New pteridinones as PLK inhibitors | PLK2, PLK4, PLK3 | HTR4 4160/4885AURKA 116/4885AURKB 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.